Building on our previous findings, the present study aimed to further explore the potential of bepridil as a targeted therapeutic agent for the modulation of TNNC1 signaling and the suppression of the metastatic phenotype of ovarian cancer cells. Here, TNNC1 is linked to ovarian cancer.